Vaxart Inc (NASDAQ:VXRT) Stock Is Shorted More

June 14, 2018 - By Paula Hilliard

The stock of Vaxart Inc (NASDAQ:VXRT) registered an increase of 86.27% in short interest. VXRT’s total short interest was 57,000 shares in June as published by FINRA. Its up 86.27% from 30,600 shares, reported previously. With 141,300 shares average volume, it will take short sellers 0 days to cover their VXRT’s short positions.

The stock decreased 2.15% or $0.07 during the last trading session, reaching $3.19. About 39,212 shares traded. Vaxart, Inc. (NASDAQ:VXRT) has declined 5.79% since June 14, 2017 and is downtrending. It has underperformed by 18.36% the S&P500.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company has market cap of $22.78 million. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus vaccines, as well as other recombinant vaccines. It currently has negative earnings. The Company’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV.

More recent Vaxart, Inc. (NASDAQ:VXRT) news were published by: Schaeffersresearch.com which released: “3 Drug Stocks Making Monster Moves” on June 04, 2018. Also Benzinga.com published the news titled: “45 Biggest Movers From Yesterday” on June 06, 2018. Streetinsider.com‘s news article titled: “Vaxart (VXRT) Says Phase 2 Trial of Teslexivir for Treatment of Condyloma Didn’t Achieve Primary Efficacy Endpoint” with publication date: June 04, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: